Skip to main content

Advertisement

SpringerLink
Log in

Selected Issues on Regulation of the Circulation of Non-Biological Complex Drugs

  • MOLECULAR-BIOLOGICAL PROBLEMS OF DRUG DESIGN AND MECHANISM OF DRUG ACTION
  • Published:
Pharmaceutical Chemistry Journal Aims and scope

An analytical review of widely discussed issues on the classification of drugs based on the methods/sources of their preparation and the complexity of their structures is presented. According to the classification, drugs are divided into three types: (A) low-molecular-weight synthetic “conventional” drugs that are completely characterized chemically; (B) biological complex drugs that are not fully characterized chemically (BCD); and (C) non-biological/synthetic complex drugs that are not fully characterized chemically (NBCD). This classification has both scientific and practical significance due to the fact that NBCDs (liposomal drugs, complex iron—carbohydrate complexes, glatiramoids, low-molecular-weight heparins) are similar to BCDs with respect to both structure (a mixture of strongly bound macromolecular fragments not amenable to isolation and complete identification) and biological/pharmacological effects (immunogenicity, insufficient information about the mechanism of action). Recent practice shows that NBCD generic versions in addition to biosimilar drugs are actually not identical to the original drugs because of differences in the manufacturing technology. For this reason, the expedited review and registration of these drugs, which is analogous to that used for conventional low-molecular-weight drugs, seems to be insufficient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. A. N. Mayeno, F. Lin, C. S. Foote, et al., Science, 250(4988), 1707 – 1708 (1990).

    Article  CAS  PubMed  Google Scholar 

  2. E. Kh. Anaev and A. G. Chuchalin, Pul’monologiya, 4, 106 – 115 (2012).

    Google Scholar 

  3. J. Varga, J. Uitto, and S. A. Jimenez, Ann. Intern. Med., 116(2), 140 – 147 (1992).

    Article  CAS  PubMed  Google Scholar 

  4. M. Wadhwa, A.-L. H. Skog, C. Bird, et al., Clin. Cancer Res., 5(6), 1353 – 1361 (1999).

    CAS  PubMed  Google Scholar 

  5. A. V. Pivnik, V. N. Tonkoglaz, and D. V. Boiko, Klin. Med. (Moscow), 3, 55 – 59 (2006).

    Google Scholar 

  6. N. N. Spirin, D. S. Kasatkin, I. O. Stepanov, et al., Zh. Nevrol. Psikhiatr., 8, 27 – 33 (2012).

    Google Scholar 

  7. F. A. Khabirov, N. N. Babicheva, T. I. Khaibullin, et al., Zh. Nevrol. Psikhiatr., 9, 113 – 117 (2012).

    Google Scholar 

  8. US Food and Drug Administration; available from: www.fda.org.

  9. Guideline on Similar Biological Medicinal Products, CHMP / 437 / 04, October 2005. European Medicines Agency; available from: http://www.ema.europa.eu/docs/enGB/documentlibrary/Scientificguideline/2009/09/WC500003517.pdf.

  10. A. N. Vasil’ev, E. V. Gavrishina, R. R. Niyazov, et al., Remedium, 9(7 – 8), 49 – 54 (2013).

    Google Scholar 

  11. A. N. Mironov, D. V. Goryachev, I. A. Proskurina, and V. A. Merkulov, Vedomosti HTsESMP, 3, 3 – 8 (2014).

    Google Scholar 

  12. Yu. B. Belousov, S. K. Zyryanova, and M. V. Davydovskaya, Zh. Nevrol. Psikhiatr., 9(2), 19 – 24 (2011).

    Google Scholar 

  13. http://pravo.gov.ru

  14. J. M. Nicholas, GaBi J., 3(2), 71 – 78 (2014).

    Article  Google Scholar 

  15. D. J. A. Crommelin, J. S. B. De Vlieger, V. Weinstein, et al., AAPS J., 16(1), 11 – 14 (2014).

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. D. S. Watson, A. N. Endsley, and L. Huang, Vaccine, 30(13), 2256 – 2272 (2012).

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. A. Yu. Baryshnikov, Vestn. Ross. Akad. Med. Nauk, 3, 23 – 31 (2012).

    PubMed  Google Scholar 

  18. A. Gabizon, H. Sheemda, and Y. Barenholz, Clin. Pharmacokinet., 42(5), 419 – 436 (2003).

    Article  CAS  PubMed  Google Scholar 

  19. J. E. Toblli, G. Cao, L. Oliveri, and M. Angerosa, Arzneim. Forsch., 59(4), 176 – 190 (2009).

    CAS  Google Scholar 

  20. C. Holloway, J. Mueller-Berghaus, B. S. Lima, et al., Ann. N. Y. Acad. Sci., 1276, 26 – 36 (2012).

    Article  PubMed  Google Scholar 

  21. J. M. Nicholas, GaBi J., 3(2), 71 – 78 (2014).

    Article  Google Scholar 

  22. M. J. Helenek, M. L. Tokars, and R. P. Lawrence, US Pat. Appl. No. 20130230565 / A1, Sept. 5, 2013; “Methods and compositions for administration of iron.”

  23. V. Yu. Shilo and N. N. Khasabov, Lech. Vrach, No. 1, 25 – 31 (2008).

  24. A. B. Pai, A. V. Boyd, C. R. McQuade, et al., Pharmacotherapy, 27(3), 343 – 350 (2007).

    Article  CAS  PubMed  Google Scholar 

  25. European Medicines Agency. Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. EMA / CHMP / SWP / 100094 / 2011.17March2011 [homepage on the internet]. 2011 Apr [cited 2014 Feb 24]. Available from: http://www.ema.europa.eu/docs/enGB/documentlibrary/Scientificguideline/2011/04/WC500105048.pdf.

  26. E. S. Lee, B. R. Park, J. S. Kim, et al., Curr. Med. Res. Opin., 29(2), 141 – 147 (2013).

    Article  CAS  PubMed  Google Scholar 

  27. J. Rottembourg, A. Kadri, E. Leonard, et al., Nephrol., Dial., Transplant., 26(10), 3262 – 3267 (2011).

    Article  CAS  Google Scholar 

  28. L. S. Scott, CNS Drugs, 27, 971 – 988 (2013).

    Article  CAS  PubMed  Google Scholar 

  29. J. Conner, J. Autoimmun. Cell Resp., 1:3, (2014); 1DOI: http://dx.doi.org/10.7243/2054–989X-1–3.

  30. H. Varcony, V. Weinstein, E. Klinger, et al., Pharmacotherapy, 10(4), 657 – 668 (2009).

    Google Scholar 

  31. T. Ziemssen and W. Schrempf, Int. Rev. Neurobiol., 79, 537 – 570 (2007).

    Article  CAS  PubMed  Google Scholar 

  32. M. Sela and M. R. Hillerman, Proc. Natl. Acad. Sci. USA, 101, Suppl. 2, 14559 (2004).

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. C. Ford, A. D. Goodman, K. Johnson, et al., Mult. Scler., 16, 342 – 350 (2010).

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. S. Bakshi, V. Chalifa-Caspi, I. Plaschkes, et al., Expert Opin. Ther. Targets, 17(4), 351 – 362 (2013).

    Article  CAS  PubMed  Google Scholar 

  35. O. Khan, P. Rieckman, A. Boiko, et al., Ann. Neurol., 73, 705 – 713 (2013).

    Article  CAS  PubMed  Google Scholar 

  36. GaBI Online www.gabionline.net/Biosimilars/General/Teva-gains-FDA-approval-for-three-times-a-week-Copaxone.

  37. E. Klinger, Eurasian Pat. No. 019998 B1 (2014), publ. date Jul. 30, 2014.

  38. Momenta. [press release]. Cambridge, MA. 2008 Jul 11 [cited 2014 Feb 24]. Available from: http://ir.momentapharma.com/releasedetail.cfm’ReleaseID=320978.

  39. Mylan Inc, NATCO Pharma Ltd. http://www.prnewswire.com/news-releases/mylan-inc-natco-pharma-ltd-to-collaborate-on-worldwide-marketing-and-distribution-of-generic-copaxoner-57430927.html.

  40. http://www.clinicaltrials.gov

  41. G. Ya. Shvarts and G. V. Ramenskaya, Khim.-farm. Zh., 46(11), 29 – 34 (2012); Pharm. Chem. J., 46(11), 656 – 660 (2012).

  42. F. Towfic, J. M. Funt, K. D. Flower, et al., PLoS One, 9:e83757. doi: 10.1371 / journal.pone.0083757 (2014).

    Article  PubMed Central  PubMed  Google Scholar 

  43. Y. Ramot, M. Rosenstock, E. Klinger, et al., Toxicol. Pathol., 40(1), 40 – 54 (2012).

    Article  CAS  PubMed  Google Scholar 

  44. http://www.tga.gov.au/pdf/euguide/ewp056198en.pdf

Download references

Author information

Authors and Affiliations

  1. I. M. Sechenov First Moscow State Medical University, Moscow, 119991, Russia

    G. Ya. Shvarts & G. V. Ramenskaya

  2. Teva LLC, Moscow, 119049, Russia

    G. Ya. Shvarts

Authors
  1. G. Ya. Shvarts
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. V. Ramenskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 49, No. 4, pp. 3 – 10, April, 2015.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shvarts, G.Y., Ramenskaya, G.V. Selected Issues on Regulation of the Circulation of Non-Biological Complex Drugs. Pharm Chem J 49, 213–219 (2015). https://doi.org/10.1007/s11094-015-1259-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11094-015-1259-z

Keywords

Search

Navigation